Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair–deficient or microsatellite instability–high primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Matthew Powell, Oleksandr Zub, Lucy Gilbert, Anthoula Koliadi et autres
0 citations
NCODA Oncology and Hematology Meeting Abstracts